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Regulation of gene expression occurs at different levels,
from DNA to protein, and through various mechanisms.
One of them is modification of the chromatin structure,
which is involved in the definition of transcriptional
active and inactive regions of the chromosomes. These
phenomena are associated with reversible chemical
modifications of the genetic material rather than with
variability within the DNA sequences inherited by the
individual and are therefore called ‘epigenetic’ modifica-
tions. Ablation of the molecular players responsible for
epigenetic modifications often gives rise to neurological
and behavioral phenotypes in humans and in mouse
models, suggesting a relevant function for chromatin
remodeling in central nervous system function, particu-
larly in the adaptive response of the brain to stimuli. We
will discuss several human disorders that are due to
altered epigenetic mechanisms, with special focus on
Rett syndrome.
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Several articles in this issue address the role of a timely and
appropriate regulation of gene expression in the function(s)
of the nervous system. Gene expression is particularly varied
in neurons, with a large proportion of the coding genome
being expressed at any time point (Geschwind 2000;
Sandberg et al. 2000) often with increased variability of
gene products due to alternative splicing of mRNA.
Additionally, in the central nervous system (CNS), given the
high level of structural and functional specialization,
transcripts that are expressed at very low levels may have
crucial roles for specific groups of cells and therefore be very
important for the function of the whole system.
Regulation of gene expression occurs at different levels,
from DNA to protein, and through various mechanisms,
some of which are rigidly pre-established and genetically
defined, whereas others are necessarily more flexible, as
they are required for an adequate response to environmental
stimuli. From the point of view of energy cost, it is more
useful for the cells to regulate expression at the earliest
possible level, i.e. gene transcription, so that mRNAs for
unnecessary products are not synthesized. This can be con-
trolled (i) by the availability, in each cell, of transcription
factors (in the appropriate activation state and in the pre-
sence of the necessary molecular partners) that bind to
specific regulating sequences upstream of the genes, allowing
their transcription through positioning of the RNA synthesis
machinery, but also (ii) by mechanisms of long-range action
of other DNA sequences, involving different regulating pro-
teins, with a transcription-enhancing or repressing effect,
and/or (iii) through the modification of the chromatin struc-
ture, which will define the accessibility of the DNA to these
transcription regulators and to the RNA polymerases. The
latter mechanisms are involved in the definition of active
and inactive regions of the chromosomes, in the dosage-
compensation processes such as the inactivation of one of
the X-chromosomes in mammalian females, and in the par-
ental imprinting of genes, which makes the expression of a
given gene allele dependent on its parental origin. These
phenomena are associated with reversible chemical modifi-
cations of the genetic material rather than with variability
within the DNA sequences inherited by the individual and
are therefore called ‘epigenetic’ modifications.
The link between epigenetic modifications and neuronal
function is an exciting new field of investigation in the
neurosciences emerging in the post-Human Genome era
(Shahbazian & Zoghbi 2002; Tucker 2001). In this review, we
will discuss the recent developments in this area of research.
Mechanisms of epigenetic modification
The study of epigenetic instability began more than 75 years
ago, when Muller (1940) recovered several examples of flies
displaying variegating eye phenotypes after X-irradiation. In
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several human diseases, phenotypic variation has normally
been attributed to differences in genetic background and the
influences of environment on that genetic background. In
disagreement with this idea, experiments in isogenic popula-
tions of model organisms such as Drosophila melanogaster
showed that phenotypic variation does persist and can be
transmitted through mitosis and meiosis. These data clearly
support the existence of mechanisms providing stable or
semi-stable regulation of gene expression apart from nucleo-
tide sequence. This regulation is achieved through the action
of epigenetic factors, chromatin-modifying enzymes that can
be divided into three distinct categories: (i) histone-modifying
enzymes which covalently acetylate, phosphorylate, ubiquiti-
nate, or methylate histones; (ii) DNA-modifying enzymes
which methylate CpG-rich sequences; and (iii) ATP-depen-
dent chromatin-remodeling complexes which can disrupt
nucleosome structure and increase accessibility to DNA
and histones, using the energy from ATP hydrolysis to
move histone octamers along DNA molecules (Becker &
Horz 2002; Gregory et al. 2001; Narlikar et al. 2002).
Eukaryotic genome assembles into chromatin; the basic
building block of chromatin is the nucleosome, which con-
tains 147 base pairs (bp) of DNA wrapped in a left-handed
superhelix 1.7 times around a core histone octamer (two
copies each of histones H2A, H2B, H3, and H4). Each core
histone contains two separated functional domains: a signa-
ture ‘histone-fold’ motif sufficient for both histone–histone
and histone–DNA contacts within the nucleosome, and NH2-
terminal and COOH-terminal ‘tail’ domains that contain sites
for post-translational modifications referred above. Histone
covalent modifications can work as recognition signals,
directing to chromatin the binding of non-histone proteins
that determine its function and subsequently the transcrip-
tional state of the genes. Nearly 40 years of research has
resulted in the documentation of a variety of post-translation
modification of the histones. The covalent modifications that
take place on histones include the acetylation of lysines, the
methylation of lysines and arginines, the phosphorylation of
serines and threonines, the ubiquitination of lysines, the
sumoylation of lysines, and the ADP-ribosylation of glutamic
acid residues. All these modifications, except methylation,
appear to be reversible. These are the histone modifications
that allow the transition between open and condensed states
and regulate the accessibility of DNA to several biological
processes such as transcription, recombination, replication,
and DNA repair. Covalent histone modifications and the his-
tone positioning constitute a potential histone code defining
actual or potential transcription sites (Jenuwein & Allis 2001;
Richards & Elgin 2002).
The acetylation of lysine residues in histone tails has sev-
eral roles in the regulation of the nucleosome, such as
decreasing the histone–DNA interactions and increasing the
accessibility of the DNA for transcription activation.
Acetylation can also regulate DNA replication, histone
deposition, and DNA repair, by recruiting proteins that have
an acetyl-lysine binding module – the bromodomain. The
histone acetyltransferase (HAT) is a multisubunit protein
responsible for the acetylation of lysines. This acetylation,
which promotes transcription, is reversed by histone deace-
tylases (HDACs) (Marmorstein & Roth 2001). Another his-
tone modification, lysine methylation, has been directly
implicated in epigenetic inheritance. Two distinct epigenetic
silencing mechanisms are linked to methylation of lysines 9
and 27 on histone H3. Heterochromatic proteins, such as
HP1, bind histone H3-containing methyl-lysine 9 and pro-
mote gene silencing. The Polycomb protein also binds to
histone H3, specifically at methyl-lysine 27, thus promoting
gene silencing during development (Sims et al. 2003). The
histone ubiquitination or sumoylation plays an important role
in the regulation of transcription either through proteosome-
dependent degradation of transcription factors or through
other mechanisms related to the recruitment of modification
complexes. Histone ubiquitination is usually involved in posi-
tive regulation of transcription, unlike sumoylation of histone
H4, which is important for transcriptional repression (Berger
2002; Iizuka & Smith 2003; Zhang 2003). Finally, serine
phosphorylation of histone H3 at Ser 10 and Ser 28 has
been correlated with mitotic chromosome condensation
(Nowak & Corces 2004). Other serine phosphorylation sites
have been identified on histone H2A, H2B, and H4. For
instance, phosphorylation of histone H2A at Ser 1 is reported
to be a hallmark for mitotic chromosome condensation
(Barber et al. 2004).
In addition to the histone modifications, DNA is also sub-
jected to covalent modifications that are important for gene
repression. So far, DNA methylation has been identified in
several eukaryotes except in yeast, Caenorhabditis elegans,
and D. melanogaster. In mammals, DNA methylation occurs
exclusively at CpG dinucleotides, and different patterns of
DNA methylation have been correlated with genome imprinting,
inactivation of the X chromosome, and embryonic develop-
ment. There are essentially two classes of DNA methyltrans-
ferases, the de novo DNA methyltransferases (DNMT3A and
DNMT3B) which define new methylation patterns, and the
maintenance DNA methyltransferases. The first identified
member of DNA methyltransferases, DNA methyltransfer-
ase 1 (DNMT1), is a maintenance DNA methyltransferase.
This enzyme uses as substrate hemi-methylated DNA and
copies the pattern already established during DNA replica-
tion. As a maintenance DNA methyltransferase, one could
expect DNMT1 levels in adult brain to be low, as neurons do
not undergo mitosis. Instead, not only the level of this pro-
tein is quite high but also the level of DNA methylation is
higher in adult brain than in other tissues (Brooks et al. 1996;
Goto et al. 1994; Inano et al. 2000; Tawa et al. 1990). DNA
methylation must have a role in the maturation process of
the brain as the ablation of DNA methylation maintenance
pathway, through a targeted disruption of the Dnmt1 gene,
in mouse CNS precursor cells (but not in postnatal neurons)
causes global DNA hypomethylation and neonatal death, due
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to defects in neuronal respiratory control of the mutant
animals (Fan et al. 2001).
DNMT3A and DNMT3B, de novo methyltransferases, are
essential for mammalian development. Both proteins might
be partially redundant, but the critical timing and mutant
outcomes of both proteins are different, as shown by the
studies of Okano and collaborators (1999) (mutant pheno-
types summarized in Table 1). DNMT3A and DNMT3B
expression studies performed by Feng and collaborators
(2005) also suggest that these proteins have a different
functional significance: while DNMT3B is predominant at
the beginning of embryonic neurogenesis, DNMT3A appears
to play a role at this developmental stage but also later, at
postnatal stages, in CNS function. Mutations in the catalytic
domain of DNMT3B gene have been recognized in a subset
of patients with the autosomal recessive human disorder
Immunodeficiency, Centromeric instability, Facial anomalies
syndrome (ICF, OMIM #242860) characterized by variable
immunological defects, centromeric heterochromatin
instability, facial anomalies, and mental retardation (Okano
et al. 1999; Xu et al. 1999).
In Neurospora, cytosine methylation depends on a con-
served DNA methyltransferase, which is directed to chroma-
tin by the histone H3 lysine methyltransferase DIM-5, linking
these two types of epigenetic modification.
Imprinting as modification of genetic
information affecting behavior
The general idea that genetic information inherited from both
parents is equivalent, except for the sex chromosomes, was
questioned 20 years ago with experiments that showed that
proper development of mice embryos required information
from both maternal and paternal genomes (McGrath & Solter
1984; Surani et al. 1984). This idea has been consolidated
with the identification of several imprinted genes, i.e. genes
that display a pattern of expression that is dependent on their
parental origin (Smith et al. 2004).
The mechanisms underlying the establishment and main-
tenance of imprinting are not clearly understood, but it is
known that the epigenetic mark of the imprinted genes
occurs early in the gametogenesis (gonocyte and oocyte
development). After the erasing of the inherited methylation
pattern, a new one is defined according to the origin of the
genetic material (the sex of the parent) (Kafri et al. 1992;
Monk et al. 1987; Sanford et al. 1987). For numerous genes,
imprinting may not be ubiquitous, but rather tissue-specific,
specific to developmental stage or species-specific
(Yamasaki et al. 2003). Interestingly, there seems to be a
differential distribution of the expression of imprinted genes
within the brain. This was elegantly demonstrated with
studies in mouse chimeras, in which cells that were disomic
for maternal genome survived especially in the neocortex,
striatum, and hippocampus, while cells disomic for paternal
genome were virtually absent in telencephalic structures but
present in the hypothalamus, preoptic area, structures
important for primary motivated behavior (Allen et al. 1995;
Keverne et al. 1996).
Many explanations for the evolution and origin of genomic
imprinting have been proposed, including regulation of gene
dosage (Solter 1988) and the conflict over parental invest-
ment (Moore 2001). Parental imprinting can be seen as a
form of selection of the regions of maternal/paternal gen-
omes contributing for the behavior of the offspring. Maternal
investment over its offspring is influenced by the paternal
contribution to the offspring genome, and the conflict cre-
ated might be solved through gene imprinting, each player’s
(mother, father, and offspring) involvement defending each
one’s best interest. An example is the involvement of the
father in determining the size of the litter and of the mother
in provisioning it (Hager & Johnstone 2003).
Clearly, a disturbance in the balance of the two imprinted
genomes can result in brain dysfunction, and imprinted
genes are recognized to play important roles in a number of
different human conditions and in altered social behavior in
mammals. Angelman’s syndrome (AS, OMIM #105830) is a
human disorder presenting severe speech delay, happy
affect, epilepsy, and movement disorders (Williams et al.
2001). Prader–Willi syndrome (PWS, OMIM #176270) is
characterized by diminished fetal activity, obesity, muscular
hypotonia, mental retardation, short stature, and small hands
and feet. The most common mutations in these two syn-
dromes are deletions of chromosome 15q, and depending on
whether the affected allele is the maternal or the paternal
one, PWS or AS will develop. Mutations in one particular
gene located on chromosome 15q, UBE3A, have also been
identified in patients with AS without deletions in 15q
(Kishino et al. 1997; Matsuura et al. 1997). UBE3A shows
an imprinted mode of inheritance, consistent with a gene
exclusively or preferentially active on the maternal chromo-
some. The absence of a functional maternal allele causes AS.
The restricted neurobehavioral phenotype of this syndrome
might suggest a brain-specific imprinting of UBE3A. In fact,
Yamasaki and collaborators (2003) showed that Ube3a-deficient
mice exhibit a neurological phenotype that resembles AS in
humans and that Ube3a in mice is imprinted specifically
in neurons but not in glial cells.
Other very interesting examples of imprinted genes with a
role in behavior are the paternally expressed genes (Peg).
The Peg1 gene (also known as Mest) is highly expressed in
various brain regions of mice and presents an imprinted
pattern, with expression of the paternal allele. Peg1-deficient
mice are viable and fertile; however, the paternal transmis-
sion of a mutant allele causes a growth retardation,
increased perinatal and postnatal lethality, and abnormal
maternal behavior, without placentophagy (Lefebvre et al.
1998). Peg3 also has an imprinted monoallelic paternal
expression. Peg3-mutant mice have a complete deficit in all
aspects of maternal behavior (retrieving, nest building, and
crouching). The hypothalamic medial preoptic area (MPOA) is
Santos et al.
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known as a regulatory center for maternal behavior, and
oxytocin released from the hypothalamic paraventricular
and supraoptic nuclei neurons controls milk ejection. The
suggestion that Peg3 could be involved in the modulation
of the ‘maternal response’ is supported by the neural expres-
sion pattern of Peg3 in hypothalamic nuclei, including MPOA,
medial amygdala, and hippocampus, and the reduced num-
ber of oxytocin-positive neurons in mutant Peg3 females
(Li et al. 1999). Interestingly, however, Szeto and collabora-
tors (2004) created a transgenic mouse in a mutant Peg3
background (Li et al. 1999) in which they were not able to
see the recovery of the wild-type phenotype; they propose
that this result could be due to the low expression level of
the transgene during early embryonic development, probably
due to the absence of important regulatory elements in the
transgene.
Chromatin remodeling and behavior
Chromatin-remodeling complexes were first identified by
genetic screens in yeast as targets of mutations that alter
the transcription of genes induced in response to extracellu-
lar signals (Winston & Carlson 1992). The identified mutant
strains were named SWi/SNF (mating type SWItching/
Sucrose Non-Fermenting). All different chromatin-remodeling
multisubunit complexes contain a core SNF2-related ATPase
region. SNF2 family members can be subdivided into several
subfamilies according to the presence of protein motifs out-
side the ATPase region. The SNF2 subfamily includes the
human BRG-1, and hBRM subunits of SWI/SNF-related com-
plexes in Drosophila and humans. The BRG1- and BRM-
associated chromatin-remodeling complexes have been
implicated indirectly in the pathology of Williams-Beuren syn-
drome (WBS, OMIM #194050), an autosomal dominant dis-
order caused by heterozygosity of a microdeletion at 7q11.2.
WBS is characterized by congenital heart disease, infantile
hypercalcemia, a characteristic facies (described as elfin
facies), and mental retardation. Socially, WBS children pre-
sent a unique social behavior. Often they take the initiative to
approach others, are overly friendly, and are always noted in
a group. However, they also present behavioral problems
such as attention deficits and anxiety (Morris & Mervis
2000). Interestingly, the Williams syndrome transcription fac-
tor (WSTF) encoded by the WBSCR9/BAZ1B gene, one of
the genes deleted in WBS, is needed to recruit BRG1 and
BRM and their associated chromatin-remodeling factors to
vitamin D-regulated promoters (Kitagawa et al. 2003).
Haploinsufficiency of this gene has been implicated as a
possible cause of hypocalcemia in WBS patients. WSTF
also interacts with ISWI, a SWI/SNF-related ATPase, to
form a chromatin-remodeling complex, WHICH, that partici-
pates in DNA replication through interaction with PCNA
(Bozhenok et al. 2002; Poot et al. 2004). On the basis of
these findings, aberrant chromatin remodeling might play a
key role in the pathophysiology of WBS. Another disorder in
which chromatin remodeling seems to be affected is Rett
syndrome (RTT), which we will explore in greater detail in the
next sections, given the abundance of recent data regarding
its pathophysiology.
MECP2 and Rett syndrome
The relevance of chromatin modification and remodeling for
the function of the mammalian nervous system was first
brought to attention when the genetic basis of the pervasive
neurodevelopmental disorder known as Rett syndrome was
clarified, in 1999 (Amir et al. 1999). This syndrome is a major
cause of mental retardation in females, affecting 1/10 000–
1/22 000 born females; it is characterized by an apparently
normal pre- and perinatal development (6–18 months of age),
followed by a growth deceleration/arrest and a loss of motor,
language, and social acquisitions, leading to lifetime mental
retardation, autistic behavior, and motor deterioration (clinical
diagnosis criteria reviewed and recently updated by Hagberg
and colleagues) (Hagberg et al. 1983; Hagberg et al. 2002).
Stereotypical hand movements (hand washing/wringing,
hand clapping/patting or hand mouthing) are often present
and constitute a hallmark of the syndrome. Pathologically, a
reduction of cortical thickness is observed, in spite of relative
preservation of neuronal number, corresponding to a mark-
edly reduced neuronal size and increased cell packing den-
sity, with loss of neuronal arborization and decreased
synaptic density (Armstrong 2001). The majority of patients
with classic RTT are heterozygous for mutations in the
MECP2 gene (Amir et al. 1999), which encodes a methyl-
CpG-binding protein, MeCP2, known to bind symmetrically
methylated CpG dinucleotides and recruit Sin3A and HDACs
to repress transcription (Jones et al. 1998).
Several animal models for the study of the MeCP2 func-
tion in vivo have been created in mice (mutants summarized
in Table 1), which mimic in many aspects Rett syndrome:
a knock-out (ko) mouse for the Mecp2 gene (Guy et al. 2001),
a mutant that possesses only the C-terminal region of the
gene (Chen et al. 2001), and a transgenic mouse, MeCP2308,
with a hypomorphic allele that truncates the protein at the
position 308 (Shahbazian et al. 2002a). All these mutants are
born normal and symptoms start to develop a few weeks
later with progressive motor deterioration, males displaying
an earlier onset and being more severely affected than
females. As in RTT patients, no gross abnormalities in the
brain were detected. The MeCP2308 mutant also presented
emotional and social behavior abnormalities along with the
motor dysfunction.
Expression of MeCP2 in mutant mice that are deficient for
the Mecp2 gene (models by Guy et al. 2001 and Chen et al.
2001) was shown to rescue the neurological RTT-like pheno-
type of mutants, the mutant mice expressing the transgene
becoming indistinguishable from wild-type (wt) littermates.
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In the study by Luikenhuis et al. (2004), the expression of a
mutant Mecp2 transgene in the postmitotic neurons of
mutant mice was sufficient to recover the RTT-like pheno-
type in these animals. This suggests that the function of
MeCP2 must be not in the embryonic development, but at
later stages. However, overexpression of MeCP2 had a dele-
terious effect both on wt and on ko mice and induced a
neurological phenotype that varied in severity according to
the protein level (Collins et al. 2004; Luikenhuis et al. 2004).
The MeCP2 protein appears to be highly regulated and its
deregulation seems to have severe consequences specifi-
cally in the brain. In mice overexpressing MeCP2 (Collins
et al. 2004), its upregulation affects pathways leading to
cerebellar and hippocampal learning and increases synaptic
plasticity, in an antagonistic way to the mental retardation
presented by RTT patients.
In the embryonic development of humans and mice,
MeCP2 expression starts to be detected very early and in
the ontogenetically older brain areas (Shahbazian et al.
2002b). However, it is only in the mature brain that MeCP2
is expressed at the strongest levels. LaSalle and collabora-
tors (2001) showed that in brain, one can find subpopulations
of cells that are MeCP2 ‘high expression’ and MeCP2 ‘low
expression’ cells. In RTT pathogenesis, the MeCP2 ‘high
expression’ cells seem to be selectively affected. The sub-
population of MeCP2 ‘high expression’ cells was more repre-
sented in developed cerebrum than in immature brain
(Balmer et al. 2002). The results by Mullaney and collabora-
tors (2004) in the rat brain further narrowed the window of
MeCP2 critical role to synaptogenesis. The authors showed
a higher expression of MeCP2 and higher number of
synapses in layer V than in layer VI of the cerebral cortex
(first generated), as well as a concordant timing between the
expression of MeCP2 and a higher number of synapses in
the granule cells of the cerebellum and in the hippocampus,
suggesting that MeCP2 might be regulating genes that are
important for synapse formation, function, or maintenance
rather than previous stages of nervous system development
(such as neuronal differentiation or migration).
Neuronal targets of MeCP2
Mutations in the MECP2 gene are responsible for hyperace-
tylation of histone H4 in cultured cells from patients with
RTT, through impaired formation of the co-repressor com-
plex Sin3A/HDAC, which in turn can affect chromatin archi-
tecture (Wan et al. 2001). Also, mutant MeCP2308 mice
display hyperacetylation of H3 in cerebral cortex and cerebel-
lum (Shahbazian et al. 2002a). Additionally, MeCP2 has been
shown to facilitate lysine 9 methylation in H3 and may serve
as a bridge between DNA methylation and histone methyla-
tion (Fuks et al. 2003; Horike et al. 2005). Finally, during
postnatal brain development, pairing of homologous 15q11–13
alleles occurs (Thatcher et al. 2005) and MeCP2 is involved in
this specific pairing that is disrupted in several neurodevelop-
mental disorders such as RTT. How disruption of these func-
tions leads to the specific developmental dysfunctions that
occur in RTT remains unknown. The identification of neuronal
targets of MeCP2 is one avenue of research that may pro-
vide a clue to RTT pathogenesis, and possibly to an increased
understanding of other pervasive developmental disorders
such as autism and AS, in which MeCP2 levels appear to
be low (Samaco et al. 2004).
Most microarray studies have failed to identify any sub-
stantial and consistent changes in transcription levels in
Mecp2-null mice (Tudor et al. 2002), clonal cell cultures
from individuals with RTT (Traynor et al. 2002), or in post-
mortem RTT brains (Colantuoni et al. 2001). These results
suggest functional redundancy between the different
methyl-binding proteins or a more focused action of MeCP2
as a selective regulator – be it region-specific actions of the
protein in the brain, action at a specific developmental stage,
involvement of MeCP2 in specific epigenetic events (such as
imprinting of certain genes), or in activity-dependent tran-
scription. In any of these scenarios, important differences
in the transcription levels of certain genes may exist in the
absence of MeCP2, but their detection will only be possible if
suitable experimental designs are used.
A recent study by Ballestar and collaborators (2005) com-
bining microarray studies, chromatin immunoprecipitation
analysis, bisulfite genomic sequencing, and treatment with
demethylating agents, in lymphoblastoid cell lines derived
from RTT patients, revealed the deregulated expression of
a number of genes, which were shown to have methylated
promotors, directly bound by MeCP2. Approximately half of
these target genes presented high expression levels in RTT
cells when compared with wt cells, whereas the remaining
half were downregulated, most likely because of an indirect
effect of MeCP2 on genes that are in turn regulating these
ones. The role of these target genes in the pathogenesis of
RTT remains to be clarified.
MeCP2 was shown to be involved in the imprinting control
region of the H19 gene (Drewell et al. 2002). H19 is an
example of a gene for which imprinting occurs for the pater-
nal allele. The promoter region of the paternal allele is highly
methylated and its silencing was shown to be methylation-
dependent and mediated by MeCP2 (Drewell et al. 2002).
However, the analysis of different imprinted genes, including
the H19 gene, in cultured T-cell clones from blood and in
brains from patients with mutations in the MECP2 gene
revealed normal monoallelic expression in all clones and
brain samples (Balmer et al. 2002), which might suggest
an in vivo redundancy amongst the methyl-binding domain-
containing (MBD) family of proteins.
Horike and collaborators (2005) recently found that DLX5,
a gene whose product is involved in the synthesis of gamma
aminobutyric acid (GABA), is upregulated in RTT. In humans,
DLX5 has an imprinted pattern with expression of the mater-
nal allele, while in mice Dlx5 is biallelically transcribed, but
Santos et al.
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preferentially from the maternal allele. The authors found
that in the cortex of Mecp2-null mice and in human lympho-
blastoid cells from individuals with RTT (i) transcription levels
were higher than normal and (ii) there was an altered parental
imprinting of the gene that was dependent on the type of
mutation. Although the target region through which MeCP2
regulates Dlx5 expression is not known yet, this strengthens
the possible link between MeCP2 and imprinting and, for the
first time, connects RTT to this epigenetic mechanism. It
also provides useful clues to RTT pathogenesis, as affected
GABA neurotransmission could explain some of the cogni-
tive symptoms of RTT.
Two other candidate targets of MeCP2 are the UBE3A and
GABRB3 genes. These are particularly interesting, as UBE3A
is linked to AS and GABRB3 (which encodes the protein
GABA receptor b3 subunit), have been consistently impli-
cated in autism, in association studies, and both disorders
present some phenotypic overlap with RTT. UBE3A and
GABRB3 levels were found to be decreased in RTT, AS,
and autism brains. Mecp2-deficient mice also display
decreased levels of Ube3a and Gabrb3, in spite of the lack
of alterations in the imprinting pattern of the Ube3a gene
(Samaco et al. 2005). A possible mechanism through which
MeCP2 regulates the expression of UBE3A has recently
been proposed: MeCP2 binding to the methylated PWS-
imprinting center at the maternal allele where the antisense
UBE3A gene resides. Mutant MeCP2 would cause an epi-
mutation at this center, affecting the expression of UBE3A
(Makedonski et al. 2005).
Experiments performed in Xenopus embryos showed that
MeCP2 targets the gene xHairy2a during development. In
the absence or presence of a mutant form of MeCP2, the
expression of the xHairy2a gene was misregulated, with
consequences in neuronal differentiation. This study showed
that MeCP2 interacts with SMRT complex via Sin3A and that
mutant MeCP2 had defective binding to SMRT co-repressor
complex. It is possible that DNA methylation and MeCP2
binding can modulate the levels of xHairy2a expression and
have an essential role in early neurogenesis (Stancheva et al.
2003).
The most interesting target of MeCP2 identified so far is
doubtlessly the gene encoding the brain-derived neuro-
trophic factor (BDNF ), one of the genes for which transcrip-
tion is regulated in a neuronal activity-dependent manner.
Data from two different studies showed that MeCP2 is
involved in the Bdnf gene silencing in the absence of neuro-
nal activation. MeCP2 was shown to bind to the methylated
rat Bdnf promoter III (equivalent to promoter IV in the
mouse) and, upon membrane depolarization of cultured cor-
tical neurons, to dissociate from the promoter and lead to a
higher transcription level of the Bdnf gene (Chen et al. 2003;
Martinowich et al. 2003). Chen and collaborators (2003) also
showed that the release of MeCP2 protein was due to cal-
cium influx that caused a phosphorylation of MeCP2. Given
the role of BDNF in development and neuronal plasticity
(McAllister et al. 1999; Binder & Scharfman 2004) and the
timing when MeCP2 demand becomes crucial, that coin-
cides with moments of synapse development and matura-
tion, the aforementioned evidence easily fits a model in
which MeCP2-regulated chromatin remodeling would under-
lie neuronal plasticity, which could explain some symptoms
of the RTT phenotype, such as reduced dendritic arborization
and complexity in some areas of the brain (Armstrong 2001)
as well as the clinical finding of mental retardation.
Methyl-DNA-binding proteins and DNA
methyltransferases
In addition to MeCP2, four other MBD-containing proteins
(MBD1, MBD2, MBD3, and MBD4) exist (Ballestar & Wolffe
2001). Interestingly, null mutations in several of these pro-
teins lead to behavioral phenotypes, as do some mutations in
DNA methyltransferases (summarized in Table 1).
MBD1 is expressed in neurons throughout the brain, with
highest concentration in the hippocampus (CA1 and DG), and
is not expressed in glia. Mice ko for the Mbd1 gene display
reduced neurogenesis in the hippocampus, perform worse
than wt animals when tested in the Morris water maze, and
have a reduction in dentate gyrus long-term potentiation
(LTP) (Zhao et al. 2003).
Mbd2–/–-mutant mothers do not present a proper nurturing
behavior of their offspring (Hendrich et al. 2001). This
phenotype resembles the Peg3-mutant mothers (discussed
above), highlighting a potential connection between Mbd2
and imprinting. However, altered expression of Peg3 or other
imprinted genes was not detected in Mbd2–/– animals. It is
possible that if differences exist, the deregulation occurs in a
localized and functionally related area of the brain, such as
MPOA of the hypothalamus. Mbd3–/– animals die before
birth, suggesting an essential role of this protein during
development (Hendrich et al. 2001). The different pheno-
types of these two mutants might be explained, in part, by
the expression pattern of the corresponding proteins.
Expression profiles of MBD2 and MBD3 in the developing
brain are not parallel: during development and in adulthood,
MBD3 is expressed in ontogenetically younger brain regions,
in contrast with MBD2 expression, that is weak in embryonic
brain, but pronounced in the adult brain (Jung et al. 2003).
In addition to RTT and WBS, there are other human dis-
orders in which mutations affecting chromatin remodeling
lead to behavioral phenotypes where, for most of the
cases, MR is a cardinal feature. Mutations in the JARID1C
gene have been recently identified in patients with X-linked
mental retardation (XLMR). The protein encoded by this gene
belongs to the ARID protein family, which contains several
DNA-binding motifs, and is involved in transcriptional regula-
tion and chromatin remodeling (Jensen et al. 2005).
All this evidence suggests a role for ‘brain chromatin’ and
its epigenetic modifications in mental retardation. This link
Chromatin remodeling and neuronal function
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seems to be established early in development and when
perturbed has consequences for life.
Chromatin remodeling and interaction with the
environment
Some chromatin modification patterns need to be rigidly pre-
established and even irreversible, such as the ones involved
in developmental determination and differentiation, relevant
to the appropriate formation of clearly defined circuits in the
nervous system. However, there are many recent pieces of
evidence suggesting that in many other cases, a process of
dynamic chromatin remodeling is connected to phenomena
of cellular and/or system response to extracellular and envir-
onmental stimuli.
The first example of this is the response to ischemia. After
cerebral ischemia, DNA methylation is known to augment in
wt mice, rendering the brain more susceptible to damage
(Endres et al. 2000). The mechanisms through which this
happens are not clear, but they might involve altered gene
expression, DNA repair mechanisms or changes in mitotic
activity. Ko animals for the Dnmt1 gene do not present, after
mild brain ischemia, this elevation in the level of DNA methy-
lation, and have a better stroke outcome than wt mice, with
reduced lesion size and higher number of neurons in the
striatum (Endres et al. 2000).
Another example is the role of chromatin modifications in
rythmicity of expression of the Clock genes. Organisms learn
how to properly respond to the environmental changes that
occur through the 24-h day or through the different seasons
of the year such as temperature and light intensity. The
mammalian core timekeeping has been identified as the
suprachiasmatic nucleus (SCN) in the hypothalamus
(Hastings & Maywood 2000) and allows mammals to adapt
behavior and physiological responses to the day: night 24-h
cycle (see Oster 2006). The entrainment of the SCN is done
by a light pulse which induces a burst of expression of the
clock genes (Per1 and Per2) and immediate early genes
(c-Fos, Fos-B, and Jun-B) (Albrecht et al. 1997; Kornhauser
et al. 1990; Morris et al. 1998). One of the mechanisms
involved in transcriptional regulation is chromatin remodeling
through histone modification. The data obtained by Crosio
et al. (2000) support the idea that circadian gene expression
might be controlled at the histone level. When a pulse of light
was given to mice kept in a 12-h light/12-h dark cycle for
2 weeks, and then for 4 days in constant dark, an increase of
the H3 phosphorylation was detected and closely accom-
panied by the expression of the early gene c-Fos. In another
study, Etchegaray and collaborators (2003) were able to
identify rhythmicity in RNA polymerase II binding and ace-
tylation of H3 in the Per1 and Per2 genes and showed that
these rhythms were synchronous in the peripheral liver oscil-
lator. It has also been demonstrated that p300, which has
intrinsic HAT activity, is part of the CLOCK/BMAL1 complex
and that the negative loop of CRY protein in the transcription
regulation of Per genes is through the p300 protein
(Etchegaray et al. 2003). Thus, in addition to mutations in
circadian genes, loss of function of genes involved in epige-
netic modification, namely acetylation and phosphorylation,
might be responsible for impairment of rhythmicity.
Activity-dependent gene transcription and
chromatin modification: role in synaptic
plasticity
Synaptic plasticity underlies the brain’s adaptive response to
the environment. The mechanisms involved operate through
post-translational modifications of proteins at the level of the
dendrites (short-term responses) but may also involve the
synthesis of new proteins through regulation of gene expres-
sion in the nucleus, when long-term responses/long-term
memories are concerned (Levenson & Sweatt 2005; West
et al. 2001). Synaptic activity induced either by external or by
endogenous stimuli leads to a calcium influx and depolariza-
tion of the membrane. This Ca2þ rise is an important element
in the activity-dependent gene transcription in the nucleus of
neurons. Ca2þ influx can be perceived by the cell in different
ways (temporal pattern of electrical activity or spatial pattern
of Ca2þ influx) and by different molecules (second messen-
gers) and the manner in which the signal gets to the nucleus
(Ca2þ channels, Calmodulin, CREB, and MAP kinase) has a
consequence in the interpretation of the different stimuli.
This leads to different pathways being activated and conse-
quently different genes activated and proteins expressed
(Bradley & Finkbeiner 2002).
In the nucleus, CREB-dependent gene expression plays a
crucial role in associating synaptic activity with long-term
changes in synaptic circuitry in many kinds of neuronal sys-
tems. The phosphorylation of CREB by PKA increases the
stability of the complex formed by CREB and CBP, a histone
acetyltransferase, and thus regulates CREB-dependent
gene expression through chromatin modification (Bito &
Takemoto-Kimura 2003). The work by Guan and collaborators
(2002) with the early response gene C/EBP also showed that
the integration of stimuli that were repeatedly presented at
independent synapses occurs at the nucleus by changes in
chromatin structure that regulate gene expression/protein
synthesis.
The data available for MeCP2 (Chen et al. 2003;
Martinowich et al. 2003) provide the first evidence strongly
supporting a link between chromatin remodeling and the
synaptic or dendritic modifications that underlie the learning
process, impaired in RTT and in many other related develop-
mental disorders associated with cognitive deficits which
share the clinical outcome of mental retardation.
It can be concluded that epigenetic modifications are essential
for proper neuronal development, survival, and function and
they may play a role in this system’s adaptive response
to the environment. We begin to have some evidence for
an involvement of chromatin remodeling in plastic CNS
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processes, such as the synaptic or dendritic modifications
underlying learning. Transcriptional changes and modification
of protein expression are known to be crucial for the estab-
lishment of many types of long-term memory. Thus, it is
conceivable that modification of chromatin could affect these
processes, either through an effect on global repression of
gene activity or through specific modification of the expres-
sion of genes involved in such processes. An increased under-
standing of the mechanisms of epigenetic modifications and
their role in neuronal function should shed light on the basis of
many human cognitive and behavioral disorders.
Note added in proof
After this article as been accepted for publication, two
independent studies revealed the impairment of synaptic
plasticity, LTP and LTD in mouse models of RTT (Asaka Y,
2005; Moretti P, 2006).
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